Related Experiment Videos
[Hemolytic anemia and renal insufficiency caused by nomifensine. Description of a case]
Minerva Medica
|November 10, 1986
Abstract:
A 38 year old patient suffered two haemolytic attacks with kidney failure following treatment with Nomiphensin (Psicronizer). The second haemolysis was only preceded by 50 mg Nomiphensin after prolonged suspension of treatment with the drug. Blood tests revealed the autoimmune nature of the haemolytic process and demonstrated the close connection with Nomiphensin intake. The personal results are compared with those of the series published earlier.
Insights
Nomiphensin (Psicronizer) can cause autoimmune hemolytic anemia and kidney failure. Even small doses after a break can trigger severe hemolytic attacks in susceptible individuals.
Area of Science:
- Pharmacology
- Nephrology
- Immunology
Background:
- Nomiphensin (Psicronizer) is an antidepressant medication.
- Drug-induced hemolytic anemia is a rare but serious adverse effect.
Observation:
- A 38-year-old patient experienced two severe hemolytic attacks with kidney failure after Nomiphensin treatment.
- The second attack occurred after a minimal 50 mg dose following a treatment suspension.
Findings:
- Blood tests confirmed the autoimmune nature of the hemolytic process.
- A direct correlation was established between Nomiphensin intake and the hemolytic episodes.
- Results align with previously published case series on Nomiphensin-induced hemolysis.
Implications:
- Highlights the potential for severe autoimmune reactions to Nomiphensin, even at low doses.
- Emphasizes the need for vigilant monitoring of patients on Nomiphensin for hematological and renal complications.
- Suggests careful consideration of Nomiphensin in patients with a history of autoimmune disorders or unexplained hemolysis.